NBIX - Neurocrine Biosciences, Inc.
| Previous Close | 114.58 |
| Open | 115.43 |
| Bid | 110.10 x 800 |
| Ask | 117.00 x 1100 |
| Day's Range | 111.90 - 116.48 |
| 52 Week Range | 57.74 - 126.98 |
| Volume | 412,677 |
| Avg. Volume | 777,831 |
| Market Cap | 10.133B |
| Beta (3Y Monthly) | 2.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.58 |
| Earnings Date | Nov 5, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 1995-12-29 |
| 1y Target Est | 134.46 |
Market Realist•4 days agoHow Acadia Pharmaceuticals Is Positioned Financially
Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will generate revenues of $56.07 million in the third quarter of 2018, representing a ~57.59% YoY (year-over-year) growth. Its net revenues grew ~87% to $57.06 million in the second quarter, from $30.5 million in the second quarter of 2017.
- PR Newswire•6 days ago
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2018 Financial Results
SAN DIEGO, Oct. 15, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday, Nov. 5, 2018. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a Company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Participants can access the live conference call by dialing 877-876-9176 (US) or 785-424-1667 (International) using the conference ID: NBIX.
- GlobeNewswire•6 days ago
New Research: Key Drivers of Growth for Neurocrine Biosciences, SS&C Technologies, Quaker Chemical, Sealed Air, KLA-Tencor, and Summit Hotel Properties — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- ACCESSWIRE•6 days ago
Today's Research Reports on Trending Tickers: Tesaro and Neurocrine Biosciences
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / U.S. markets bounced on Friday, erasing some of the losses for the week, as the third quarter earnings season kicked off. The Dow Jones Industrial Average ...
Markit•10 days agoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
- Zacks•11 days ago
Neurocrine Inks Deal with Private Biotech to Make CNS Drugs
Neurocrine (NBIX) collaborates with Jnana Therapeutics to develop novel small-molecule therapies for multiple targets of central nervous system (CNS) disorders.
- PR Newswire•12 days ago
Neurocrine Biosciences and Jnana Therapeutics Enter Strategic Collaboration to Discover Novel Medicines to Treat Central Nervous System Disorders
SAN DIEGO and BOSTON, Oct. 9, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) and Jnana Therapeutics Inc. today announced that they have entered into a research collaboration aimed at discovering novel small molecule therapeutics for multiple targets for central nervous system (CNS) disorders. The collaboration will leverage Jnana's proprietary drug discovery platform across the solute carrier (SLC) family of transporters and Neurocrine's research and development expertise in CNS disorders to advance new medicines.
Market Realist•12 days agoA Financial Overview of Neurocrine Biosciences in October
Neurocrine Biosciences’ (NBIX) revenues grew from $6.3 million in the second quarter of 2017 to $96.9 million in the second quarter. The company reported net revenues of $168.0 million in the first half of this year, which grew from $6.3 million in the first half of 2017. Wall Street analysts expect Neurocrine Biosciences to generate revenues of $151.8 million in the third quarter.
Market Realist•12 days agoAnalysts Are Mostly Positive on Neurocrine Biosciences
Neurocrine Biosciences (NBIX) develops and commercializes therapies for neurology and endocrine disorders. Neurocrine Biosciences’ Ingrezza became the first FDA-approved drug to be approved for the treatment of individuals with tardive dyskinesia. Neurocrine Biosciences’ Ingrezza competes with Teva Pharmaceutical’s (TEVA) Austedo in the tardive dyskinesia drugs market.
- Zacks•13 days ago
AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis
AbbVie (ABBV) and Neurocrine receive Canadian approval for Orilissa, for the treatment of moderate to severe pain associated with endometriosis.
- CNW Group•16 days ago
AbbVie Receives Health Canada Approval of ORILISSA™ (elagolix) for the Treatment of Moderate to Severe Pain Associated with Endometriosis
AbbVie Receives Health Canada Approval of ORILISSA™ (elagolix) for the Treatment of Moderate to Severe Pain Associated with Endometriosis
- Zacks•16 days ago
UTHR vs. NBIX: Which Stock Is the Better Value Option?
UTHR vs. NBIX: Which Stock Is the Better Value Option?
- PR Newswire•20 days ago
Neurocrine Biosciences to Present New Long-Term Data Analyses on INGREZZA® (valbenazine) at the 2018 International Congress of Parkinson's Disease and Movement Disorders
SAN DIEGO, Oct. 1, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced it will present new long-term data analyses on INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), at the 2018 International Congress of Parkinson's Disease and Movement Disorders (MDS) in Hong Kong, Oct. 5-9, 2018. "Neurocrine Biosciences is committed to understanding the severity of movement disorder symptoms in patients living with tardive dyskinesia and to better understand how these symptoms manifest across body regions," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences.
- Motley Fool•21 days ago
Here's What Could Cause Neurocrine Biosciences Shares to Skyrocket
This fast-growing biotech is on track for significant earnings growth.
- Motley Fool•23 days ago
Healthcare: 2 Hot Biotech Stocks on Our Radar
Opportunities ahead could make it the perfect time to add these biotechs to your portfolio.
Markit•last monthSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Markit•last monthSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
Market Realist•last monthNeurocrine Biosciences: Analysts Are Mostly Positive
On September 13, Neurocrine Biosciences’ (NBIX) stock price closed at $120.88—an ~0.65% decline from its close of $121.67 the previous day. On September 13, Neurocrine Biosciences’ stock price closed at $120.88, which is ~116% growth from its 52-week low of $55.95 on September 19, 2017.
Market Realist•last monthA Financial Overview of Supernus Pharmaceuticals in September
In the second quarter, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in the second quarter of 2017. In the first half, Supernus Pharmaceuticals generated net revenues of $190.0 million compared to $133.4 million in the first half of 2017.
Market Realist•last monthSupernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September
On September 11, Supernus Pharmaceuticals (SUPN) stock closed at $48.80, up 1.99% from its closing price of $47.85 on September 10. The company’s September 11 stock price was 26.0% below its 52-week high of $61.25 on June 29. Supernus Pharmaceuticals hit its 52-week low of $33.30 on November 7, 2017.
- Benzinga•last month
A Double Pair Trade: Morgan Stanley Buys 2 Biotechs, Sells 2 Others
Biotech plays are numerous, and Morgan Stanley has a few recommendations to pare and prop a pharma portfolio. The Ratings Analyst Jeffrey Hung initiated coverage of: Alder Biopharmaceuticals Inc (NASDAQ: ...
- Investor's Business Daily•last month
Stock Market Forecast: More Gains, More Volatility
The stock market forecast by big money managers and strategists is for more gains, but likely more modest gains, while volatility rises.
- PR Newswire•2 months ago
Neurocrine Biosciences to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
SAN DIEGO, Sept. 5, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) will present at the Morgan Stanley 16th Annual Global Healthcare Conference at 8:10 a.m. ET on Wednesday, Sept. 12, 2018, in New York City. Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at http://www.neurocrine.com.
Markit•2 months agoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Markit•2 months agoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding NBIX totaled $186 million.
